Pharming Group (OTCMKTS:PHGUF) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued on Saturday. The firm presently has a $1.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s target price suggests a potential downside of 5.91% from the company’s previous close.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

A number of other brokerages have also issued reports on PHGUF. ValuEngine lowered Pharming Group from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. HC Wainwright reiterated a “buy” rating on shares of Pharming Group in a research report on Thursday, October 26th.

Pharming Group (OTCMKTS PHGUF) opened at $1.86 on Friday. The company has a debt-to-equity ratio of 11.47, a quick ratio of 0.99 and a current ratio of 1.31. The stock has a market capitalization of $1,015.86, a price-to-earnings ratio of -16.91 and a beta of 1.95. Pharming Group has a one year low of $0.30 and a one year high of $1.86.

Pharming Group (OTCMKTS:PHGUF) last issued its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Pharming Group had a negative net margin of 69.48% and a negative return on equity of 259.69%. equities research analysts predict that Pharming Group will post -0.07 earnings per share for the current year.

WARNING: “Pharming Group (PHGUF) Upgraded to Strong-Buy at Zacks Investment Research” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/01/21/pharming-group-phguf-upgraded-to-strong-buy-at-zacks-investment-research.html.

About Pharming Group

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.